These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33168612)

  • 1. Adverse Events Associated with Nifurtimox Treatment for Chagas Disease in Children and Adults.
    Berenstein AJ; Falk N; Moscatelli G; Moroni S; González N; Garcia-Bournissen F; Ballering G; Freilij H; Altcheh J
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults.
    Falk N; Berenstein AJ; Moscatelli G; Moroni S; González N; Ballering G; Freilij H; Altcheh J
    Antimicrob Agents Chemother; 2022 May; 66(5):e0202121. PubMed ID: 35416710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2001-2021.
    Abbott A; Montgomery SP; Chancey RJ
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(10):371-374. PubMed ID: 35271563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).
    Altcheh J; Castro L; Dib JC; Grossmann U; Huang E; Moscatelli G; Pinto Rocha JJ; Ramírez TE;
    PLoS Negl Trop Dis; 2021 Jan; 15(1):e0008912. PubMed ID: 33412557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults.
    Olivera MJ; Cucunubá ZM; Álvarez CA; Nicholls RS
    Am J Trop Med Hyg; 2015 Dec; 93(6):1224-1230. PubMed ID: 26392162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail.
    Crespillo-Andújar C; Chamorro-Tojeiro S; Norman F; Monge-Maillo B; López-Vélez R; Pérez-Molina JA
    Clin Microbiol Infect; 2018 Dec; 24(12):1344.e1-1344.e4. PubMed ID: 29906591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States.
    Forsyth CJ; Hernandez S; Olmedo W; Abuhamidah A; Traina MI; Sanchez DR; Soverow J; Meymandi SK
    Clin Infect Dis; 2016 Oct; 63(8):1056-1062. PubMed ID: 27432838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE).
    Altcheh J; Sierra V; Ramirez T; Pinto Rocha JJ; Grossmann U; Huang E; Moscatelli G; Ding O
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0119322. PubMed ID: 36975790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease.
    Moroni S; Marson ME; Moscatelli G; Mastrantonio G; Bisio M; Gonzalez N; Ballering G; Altcheh J; García-Bournissen F
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007647. PubMed ID: 31415566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas' disease.
    Jackson Y; Wyssa B; Chappuis F
    J Antimicrob Chemother; 2020 Mar; 75(3):690-696. PubMed ID: 31754690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.
    Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R
    Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.
    Bianchi F; Cucunubá Z; Guhl F; González NL; Freilij H; Nicholls RS; Ramírez JD; Montilla M; Flórez AC; Rosas F; Saavedra V; Silva N
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003465. PubMed ID: 25723465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term comparative pharmacovigilance of orally transmitted Chagas disease: first report.
    Alarcón de Noya B; Ruiz-Guevara R; Noya O; Castro J; Ossenkopp J; Díaz-Bello Z; Colmenares C; Suárez JA; Noya-Alarcón O; Naranjo L; Gutiérrez H; Quinci G; Torres J
    Expert Rev Anti Infect Ther; 2017 Mar; 15(3):319-325. PubMed ID: 28132566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance and safety of nifurtimox in patients with chronic chagas disease.
    Jackson Y; Alirol E; Getaz L; Wolff H; Combescure C; Chappuis F
    Clin Infect Dis; 2010 Nov; 51(10):e69-75. PubMed ID: 20932171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
    Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
    Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions for CAM and conventional drugs detected in a network of physicians certified to prescribe CAM drugs.
    Tabali M; Ostermann T; Jeschke E; Witt CM; Matthes H
    J Manag Care Pharm; 2012; 18(6):427-38. PubMed ID: 22839683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis.
    Ciapponi A; Barreira F; Perelli L; Bardach A; Gascón J; Molina I; Morillo C; Prado N; Riarte A; Torrico F; Ribeiro I; Villar JC; Sosa-Estani S
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008529. PubMed ID: 32804966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nifurtimox, a bright future for treatment of Chagas disease].
    Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
    Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on nifurtimox for treatment of Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2021 Apr; 57(4):251-263. PubMed ID: 33851689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease.
    Olivera MJ; Cucunubá ZM; Valencia-Hernández CA; Herazo R; Agreda-Rudenko D; Flórez C; Duque S; Nicholls RS
    PLoS One; 2017; 12(9):e0185033. PubMed ID: 28949997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.